Compounds according to Formula (I) below:
wherein R
1
, R
2
, R
3
, and R
4
are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
Compounds according to Formula (I):
wherein R
1
, R
2
, R
3
, and R
4
are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
[EN] CHROMAN COMPOUNDS AS 5-HT1B ANTAGONISTS<br/>[FR] COMPOSES CHROMANE UTILISES EN TANT QU'ANTAGONISTES DES 5-HT1B
申请人:ASTRAZENECA AB
公开号:WO2007053095A1
公开(公告)日:2007-05-10
[EN] Chroman derivatives according to formula (I), wherein R1, R2, R3 and R4 are as defined in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same. The compounds are 5-HT1B antagonists and are useful in the treatment of mood and anxiety disorders .as well as cognitive disorders. [FR] L'invention concerne des dérivés de chromane de formule (I) dans laquelle R1, R2, R3, et R4 sont tels que définis dans la description, des sels pharmaceutiquement acceptables de ces dérivés, des procédés de production correspondants, des compositions pharmaceutiques les contenant, ainsi que des procédés d'utilisation desdits composés. Ces composés sont des antagonistes des 5-HT1B et peuvent servir à traiter les troubles de l'humeur et les troubles anxieux, ainsi que les troubles cognitifs.